Innovent Biologics licenses anti-CD40L antibody IBI355 to Spero in deal worth about USD 1.1 billion

PUBT · 2d ago
Innovent Biologics licenses anti-CD40L antibody IBI355 to Spero in deal worth about USD 1.1 billion
  • Innovent Biologics licensed IBI355 (SP001), a Phase 2-ready Fc-silent anti-CD40L antibody, to Spero in an exclusive deal outside Greater China.
  • Spero secured global rights excluding Greater China for development, manufacturing, research, commercialization; Innovent retained rights in Mainland China, Hong Kong, Macau, Taiwan.
  • Innovent will receive an upfront payment; eligible for development, regulatory, commercial milestones totaling about USD 1.1 billion.
  • Agreement includes tiered royalties on net sales in Spero’s territories.
  • Spero targets a Phase 2 start in IgG4-related disease in Q2 2027; Innovent plans a China Phase 2 in Sjögren’s disease by early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN03988) on July 14, 2026, and is solely responsible for the information contained therein.